Lupin announced the launch of the first generic version of Pred Forte® (Prednisolone Acetate) Ophthalmic Suspension USP, 1% in the United States. Being the first generic to be approved and launched, the company is entitled to 180-day competitive generic therapy (CGT) exclusivity.
Prednisolone Acetate Ophthalmic Suspension USP, 1% is a generic equivalent of Pred Forte® Ophthalmic Suspension, 1% of AbbVie, Inc. and is indicated for the treatment of steroid responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of
the globe. Pred Forte® had estimated annual sales of USD 198 million in the U.S. (IQVIA MAT August 2024).